Analysts think AVTX stock price could increase by 519%
Jul 09, 2025, 11:25 AM
71.81%
What does AVTX do
Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
10 analysts think AVTX stock price will increase by 519.14%. The current median analyst target is $30.09 compared to a current stock price of $4.86. The lowest analysts target is $15.15 and the highest analyst target is $50.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.